RE: My logic says20 May 2021 12:25
Yeah, the whole point of the BOD doing it as a special dividend is that, to realise full value, we have to be prepared to take our money in chunks. Think of it this way: EUA is worth to us, say, £3/share between now and 2030. The BOD has two offers (they have more, but let's say two).
1. A full company sale now for £1.50. So that's it. That's all you'll get if you take the money and run. You lose £1.50.
2. A part-sale of assets, for £1.00. So, you get that now, and then annual dividends or another special dividend for the JV down the line (valued at PGM prices then, not now). You gain the full £3.00, but you might not get it all for a decade or so depending on how things pan out.
This benefits everyone: it reduces up-front cash on the part of the buyer; it maximises our gains over time; it means EUA and its shareholders realise full value of the assets and benefit from rising PGM prices too.
A different way of thinking about it is that we're effectively lending the eventual purchaser of Rosgeo the money now that they'll pay back to us at a stonking interest rate of hundreds of percent. This benefits them as it means they have less actual financing need. Let's say they pay $10bn eventually for our full £3, but only (for example) $4bn up front with another $6bn down the line. This is far better than a full company sale, which would simply represent us choosing to dilute our own profits and it would only benefit banks: the purchaser would front up an extra $2bn, but the overall cost to them would still be in excess of $6bn after a decade of interest and/or foregone investment elsewhere. Even if they're paying it down, it wouldn't be pretty: at least another billion dollars, possibly more. Even AirBnB had to pay over 10% recently for a loan of $1bn, how much would it cost to finance $6bn in a Russian metals project? I reckon the $6bn up front cost for a full buyout would be getting on for the $10bn they'll pay (in this example) anyway. So, it's far better for all concerned to "borrow" from us patient shareholders with an IOU to pay that money out as cash once MT has generated spectacular revenues for them for a few years.